CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced a top line summary from its recently completed proof of concept clinical trial for its patent pending, abuse deterrent, sustained release, oral oxycodone formulation COL-003. COL-003 utilizes Collegium’s DETERx™ technology and is a sustained release oral dosage form designed to be more resistant to tampering and abuse than traditional formulations of the drug. This product has undergone extensive in vitro testing and has met its development endpoints for dissolution and in vitro abuse simulation testing. Based on these studies the product is expected to be effective in deterring abuse by oral administration (e.g. chewing, crushing), intravenous injection and nasal administration (i.e. snorting). The proof of concept study was designed to assess the pharmacokinetics of COL-003 under various conditions in healthy subjects.
